The completion of the last patient's last visit in a clinical trial is a significant milestone in drug development. It indicates that the company is moving forward with its plans and is closer to potentially bringing a new product to market. This could have a positive impact on the company's stock as it may increase investor confidence in the company's ability to deliver on its pipeline.